Update
$Icecure Medical (ICCM.US)$ IceCure Medical Announces That A Large Number Of Public Comments Have Been Posted From Key Stakeholders Ahead Of The U.S. FDA Medical Device Advisory Committee Panel For Marketing Authorization Of ProSense Cryoablation In Early-Stage Low Risk Breast Cancer, Which Is Scheduled To Take Place On Thursday, November 7, 2024
Comments from key stakeholders, including doctors, nurses, researchers, and breast cancer patients, are available on FDA websiteFDA Advisory Panel providing recommendations and vote on information concerning the benefit-risk profile for a De Novo marketing submission of the IceCure ProSense Cryoablation System in early-stage low risk breast cancer scheduled for November 7, 2024
Comments from key stakeholders, including doctors, nurses, researchers, and breast cancer patients, are available on FDA websiteFDA Advisory Panel providing recommendations and vote on information concerning the benefit-risk profile for a De Novo marketing submission of the IceCure ProSense Cryoablation System in early-stage low risk breast cancer scheduled for November 7, 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
